https://scholars.lib.ntu.edu.tw/handle/123456789/628839
標題: | Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC | 作者: | Wu, Yi-Long Lu, Shun CHIH-HSIN YANG Zhou, Jianying Seto, Takashi Ahn, Myung-Ju Su, Wu-Chou Yamamoto, Noboru Kim, Dong-Wan Paolini, Jolanda Usari, Tiziana Iadeluca, Laura Wilner, Keith D Goto, Koichi |
關鍵字: | Asia; Crizotinib; NSCLC; Phase 2; ROS1 | 公開日期: | 十月-2022 | 卷: | 3 | 期: | 10 | 來源出版物: | JTO clinical and research reports | 摘要: | Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present the final OS, quality of life (QoL), and safety data after an additional 3 years of follow-up. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628839 | ISSN: | 26663643 | DOI: | 10.1016/j.jtocrr.2022.100406 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。